Assembly Biosciences, Inc. (NASDAQ:ASMB) Brief Update of Interest

Assembly Biosciences, Inc. ( NASDAQ:ASMB – Get Free Report ) received a significant drop in short interest in July. As of July 31st, there was short interest totaling 12,300 shares, a decrease of 14.6% from July 15th’s total of 14,400 shares. Currently, 0.3% of the company’s shares are short sold. Based on an average trading volume of 15,800 shares, the short interest rate is currently 0.8 days.

Assembly Biosciences stock performance

Shares of ASMB opened at $14.30 on Monday. Assembly Biosciences has a one year low of $7.69 and a one year high of $20.04. The company has a 50 day simple moving average of $14.40 and a two hundred day simple moving average of $13.68.

Insider Trading at Assembly Biosciences

In other Assembly Biosciences news, majority shareholder Alexander Schornstein purchased 4,562 shares of the business’s stock in a transaction dated Wednesday, July 3rd. The stock was purchased at an average price of $12.29 per share, for a total transaction of $56,066.98. Following the acquisition, the insider now directly owns 688,675 shares of the company’s stock, valued at $8,463,815.75. The acquisition was disclosed in a legal filing with the SEC, which is available via this link. In other news, major shareholder Alexander Schornstein purchased 4,562 shares of Assembly Biosciences stock in a transaction dated Wednesday, July 3rd. The shares were acquired at an average cost of $12.29 per share, with a total value of $56,066.98. Following the completion of the purchase, the insider now owns 688,675 shares in the company, valued at $8,463,815.75. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available via this link. Also, Director John G. Mchutchison sold 2,117 shares of the stock in a transaction dated Thursday, May 23rd. The stock was sold at an average price of $14.93, for a total value of $31,606.81. Following the sale, the director now owns 19,104 shares in the company, valued at approximately $285,222.72. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 2,690 shares of company stock valued at $40,162. Corporate insiders own 5.10% of the company’s shares.

Hedge funds weigh on Assembly Biosciences

A number of hedge funds have recently added to or reduced their stakes in ASMB. Renaissance Technologies LLC raised its position in Assembly Biosciences by 39.2% in the second quarter. Renaissance Technologies LLC now owns 54,911 shares of the biopharmaceutical company’s stock worth $753,000 after buying an additional 15,451 shares during the period. Armistice Capital LLC bought a new position in Assembly Biosciences in the second quarter worth $6,421,000. Acadian Asset Management LLC boosted its holdings in Assembly Biosciences by 131.0% in the second quarter. Acadian Asset Management LLC now owns 13,558 shares of the biopharmaceutical company’s stock worth $184,000 after buying an additional 7,690 shares during the period. Marquette Asset Management LLC acquired a new stake in Assembly Biosciences in the 4th quarter valued at $45,000. Finally, Acuitas Investments LLC acquired a new stake in Assembly Biosciences in the 4th quarter valued at $218,000. 19.92% of the shares are currently held by hedge funds and other institutional investors.

Changes in Analyst Ratings

A number of equities research analysts recently issued reports on the company. StockNews.com upgraded Assembly Biosciences from a “hold” rating to a “buy” rating in a research report on Friday, May 10th. HC Wainwright reiterated a “neutral” rating on shares of Assembly Biosciences in a research report on Thursday, June 20th.

Read our latest report on Assembly Biosciences

About Assembly Biosciences

(Get a free report)

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It is developing ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b to treat recurrent genital herpes; ABI-1179, which is in phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule, orally bioavailable, hepatitis delta virus entry inhibitor, which is in phase 1a clinical trial.

Featured stories

Get news and reviews for Assembly Biosciences Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Assembly Biosciences and related companies with MarketBeat.com ‘s FREE daily email newsletter.